The Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.
Migraine Overview
Migraine is ranked globally as the seventh most disabling disease among all diseases (responsiblefor 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among allneurological disorders. The Migraine symptoms include – severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.
Some of the key facts of the Migraine Market Report
- The Migraine market size was estimated at USD 6,960.14 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Among the 7MM, the United States is estimated to account for a major market share of the overall market size of Migraine in 2021
- Migraine is a debilitating primary headache disorder characterized by recurrent unilateral (one-sided) pulsatile headaches
- According to the Migraine Research Foundation, migraine is an extraordinarily prevalent neurological disease, affecting 1 billion men, women, and children worldwide
- In the United States, around 39 Million men, women, and children are affected by migraine
- Key Migraine Companies: Zosano Pharma, Axsome Therapeutics, Impel NeuroPharma, Biohaven Pharmaceuticals, and others
- Key Migraine Therapies: BHV-3500, Atogepan, INP104, AXS-07, Zolmitriptan transderma, and others
- The Migraine epidemiology based on gender analyzed that the prevalence of Migraine is more among females as compared to males
Get a Free sample for the Migraine Market Report
Key benefits of the Migraine Market report:
- The migraine market report covers a descriptive overview and comprehensive insight of the Migraine Epidemiology and Migraine market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Migraine market report provides insights on the current and emerging therapies.
- The migraine market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Migraine market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Migraine market.
Discover more about therapies set to grab major Migraine market share @ Migraine market forecast
Migraine Epidemiology Segmentation:
The Migraine market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Migraine
- Prevalent Cases of Migraine by severity
- Gender-specific Prevalence of Migraine
- Diagnosed Cases of Episodic and Chronic Migraine
Migraine Market
The dynamics of the Migraine market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as INP104, AXS-07, and others during the forecasted period 2019-2032.
“The Migraine treatment market looks promising as the market is emerging with newer treatments that have recently been approved by the FDA and are anticipated for approval in the coming years. A large number of clinical phase trials are being done to examine and evaluate promising investigational therapies and their much awaited launch owing towards a robust therapeutic treatment market the and bolstering the treatment response as a whole.”
Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiological Insights
Emerging Migraine Therapies and Key Companies
- BHV-3500: AbbVie
- Atogepan: Zosano Pharma
- INP104: Axsome Therapeutics
- AXS-07: Impel NeuroPharma
- Zolmitriptan transderma: Biohaven Pharmaceuticals
Scope of the Migraine Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Migraine Companies: Zosano Pharma, Axsome Therapeutics, Impel NeuroPharma, Biohaven Pharmaceuticals, and others
- Key Migraine Therapies: BHV-3500, Atogepan, INP104, AXS-07, Zolmitriptan transderma, and others
- Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
- Migraine Market Dynamics: Migraine market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Migraine Market Access and Reimbursement
Table of Contents
1. Migraine Market Report Introduction
2. Executive Summary for Migraine
3. SWOT analysis of Migraine
4. Migraine Patient Share (%) Overview at a Glance
5. Migraine Market Overview at a Glance
6. Migraine Disease Background and Overview
7. Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Migraine
9. Migraine Current Treatment and Medical Practices
10. Migraine Unmet Needs
11. Migraine Emerging Therapies
12. Migraine Market Outlook
13. Country-Wise Migraine Market Analysis (2019–2032)
14. Migraine Market Access and Reimbursement of Therapies
15. Migraine Market drivers
16. Migraine Market barriers
17. Migraine Appendix
18. Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Migraine treatment, visit @ Migraine Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/